حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Cardiex Ltd
CDXCardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia. Address: 55 Lime Street, Sydney, NSW, Australia, 2000
Analytics
سعر الهدف في وول ستريت
0.77 AUDنسبة السعر إلى الأرباح
–العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية CDX
تحليلات الأرباح CDX
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح CDX
تقييم الأسهم CDX
المالية CDX
نتائج | 2019 | ديناميات |